Replies to post #778010 on NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

It’s becoming clear now: Northwest Biotherapeutics never needed to stretch the DCVax-L label into other cancers right away. The UK has already put the right legal structure in place (SI 2025 No. 87) which allows personalized, patient-specific cell therapies like DCVax-L to be manufactured and supplied without a full marketing authorization, as long as it’s prescribed for a named patient. That means DCVax-L can already be used today for GBM and for other cancers like breast, lung, pancreatic, or pediatric gliomas, legally, safely, and under full MHRA oversight.

This dramatically changes the calculus. Rather than risking delays or rejection by asking for a broad, multi-cancer label, NWBO can stay laser-focused on what’s already proven: newly diagnosed GBM, recurrent GBM, and potentially related glioma types. That indication is backed by a completed Phase 3 trial, peer-reviewed results in JAMA Oncology, a UK PIM designation, and real-world usage already underway in the UK. There’s no regulatory need to complicate the initial application with expanded claims, especially when Specials access for other indications is already live.

And here’s the key: this makes the approval process more streamlined than many people realize. The MHRA doesn’t need to review unsubmitted data or resolve how DCVax-L fits into other oncology markets. It only needs to evaluate the GBM application on its own clean merits, an indication it has already supported through PIM, and one that aligns with the exact legal framework already being used under SI 87. The company isn’t trying to open every door at once, it’s unlocking the first one with maximum precision.

There’s also no pricing bottleneck at this stage. NICE review only begins after MHRA approval is granted. In the meantime, GBM patients are already receiving DCVax-L in the UK under SI 87, some through IFR (Individual Funding Requests), others through private payment. So this isn’t about waiting for the system to start working. The system is already working. The MAA simply turns what’s already happening into something scalable and reimbursed.

That’s why sticking to GBM first isn’t just safe, it’s strategic. It allows the MHRA to move forward without scope creep, keeps the application laser-focused, and accelerates time to approval. Once granted, the company can still legally supply DCVax-L to non-GBM patients under the very same SI 87 framework, without waiting years for formal label expansion. The immune engine is already running, this just gives it a public green light.

This is not a limitation, it’s rollout discipline. GBM is the gateway. SI 87 is the silent delivery system behind the curtain. The label stays narrow. The footprint stays wide. And the approval process, instead of dragging into ambiguity, becomes exactly what it was meant to be: targeted, evidence-based, and ready.

[meirluc]

"Once DCVax-L is approved for GBM, future use for that indication will shift under the marketing authorization. However, SI 87 will remain fully valid for all other cancer types, allowing physicians to prescribe it for off-label use without waiting for new clinical trials or formal extensions of the label"

Could this imply perhaps that if sufficient data is gathered that the efficacy of DCVax-L
treatment of a large enough number of patients suffering from various cancers
(e.g. pancreatic or breast cancer) is impressive, then even in the absence of
trials, DCVax-L could be approved for those indications. Alternatively, some
follow up trials may be required but those could be much smaller confirmatory
trials with substantially fewer patients than would have been enrolled prior to SI 87.